Special Issue "Advances in CAR-T Cell Therapy"
Deadline for manuscript submissions: 30 June 2022 | Viewed by 655
Over the past few decades, academic laboratories have developed techniques to manipulate human cells in an effort to combat many diseases, but most notably cancer. Among the human cells that have been evaluated for drug development, T lymphocytes have been particularly attractive substrates for the development of cellular therapies due to their ability to be engineered, amplified and sustained in a memory state beyond the resolution of disease to prevent recurrence. The most exciting T-cell therapy to date has been the development of chimeric antigen receptor modified T cells, commonly referred to as CAR-T cells. CAR-T cells have proven to be a game changer for some very aggressive tumors, with responses exceeding 50% in situations where palliation was previously the only option. CAR-T therapy has been most widely developed to target CD19, and through this foundation we have learned about the toxicity of CAR-T cells, their mechanism of action and reasons for therapeutic failure. The research into CAR-T cells is growing exponentially, reaching new understanding and new indications regularly.
This special issue will highlight several of the above issues and summarize where the field lies currently. Topics will include insights into CAR-T toxicity, disease relapse after CAR-T therapy, new indications for CAR-T cells and how to improve CAR-T technology.
Dr. Natasha Kekre
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- CAR-T cells
- Cytokine release syndrome